Department of Hygiene, Epidemiology & Medical Statistics, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
5th Department of Internal Medicine & Infectious Diseases Unit, Evaggelismos General Hospital, Athens, Greece.
PLoS One. 2020 Mar 30;15(3):e0230730. doi: 10.1371/journal.pone.0230730. eCollection 2020.
Although combined antiretroviral therapy has substantially improved the prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general population, mainly due to higher prevalence of non-HIV-related comorbidities, including cardiovascular diseases (CVD). We assessed the prevalence of CVD risk and its contributing factors in adult PLHIV versus general population controls in Greece.
Cross-sectional comparison of PLHIV (Athens-Multicenter-AIDS-Cohort-Study; AMACS) versus general population controls (National health examination survey; EMENO).
All HIV-infected adults with ≥1 measurement of interest (blood pressure, lipids, glucose, weight, height) between 2012-2014 and all EMENO participants (2014-2016) were included. Ten-year total CVD risk was estimated using the Framingham (FRS) or the Systematic Coronary Risk Evaluation (SCORE) equations.
5839 PLHIV (median age:41.6 years, 85.4% males) and 4820 controls (median age:48 years, 48.4% males) were included. Adjusting for age, sex and origin, PLHIV were more likely to be current smokers (adjusted OR:1.53 [95% CI:1.35-1.74]) and dyslipidemic (aOR:1.18; [1.04-1.34]), less likely to be obese (aOR:0.44 [0.38-0.52], with no differences in hypertension, diabetes or high (≥20%) FRS but with greater odds of high (≥5%) SCORE (aOR:1.55 [1.05-2.30]). Further adjustment for educational level, anti-HCV positivity and BMI showed higher prevalence of hypertension in PLHIV.
Despite the relative absence of obesity, PLHIV have higher prevalence of traditional CVD risk factors and higher risk of fatal CVD compared to general population. Regular screening and early management of CVD risk factors in PLHIV should be of high priority for CVD prevention.
尽管联合抗逆转录病毒疗法极大地改善了艾滋病毒感染者(PLHIV)的预后,但与普通人群相比,死亡率仍然较高,主要是由于非 HIV 相关合并症(包括心血管疾病 [CVD])的患病率较高。我们评估了希腊成年 PLHIV 与普通人群对照者 CVD 风险的患病率及其相关因素。
PLHIV(雅典多中心艾滋病队列研究;AMACS)与普通人群对照者(国家健康检查调查;EMENO)的横断面比较。
所有在 2012-2014 年期间至少有一次感兴趣的测量值(血压、血脂、血糖、体重、身高)的 HIV 感染成年患者和所有 EMENO 参与者(2014-2016 年)均被纳入。使用 Framingham(FRS)或系统性冠状动脉风险评估(SCORE)方程估计 10 年总 CVD 风险。
共纳入 5839 例 PLHIV(中位年龄:41.6 岁,85.4%为男性)和 4820 例对照者(中位年龄:48 岁,48.4%为男性)。调整年龄、性别和原籍国后,PLHIV 更有可能是当前吸烟者(调整后的 OR:1.53 [95%CI:1.35-1.74])和血脂异常(aOR:1.18;[1.04-1.34]),不太可能肥胖(aOR:0.44 [0.38-0.52]),高血压、糖尿病或高(≥20%)FRS 无差异,但高(≥5%)SCORE 的几率更高(aOR:1.55 [1.05-2.30])。进一步调整教育程度、抗 HCV 阳性和 BMI 后,PLHIV 高血压患病率更高。
尽管肥胖症相对少见,但 PLHIV 与普通人群相比,传统 CVD 危险因素的患病率更高,致命性 CVD 的风险更高。PLHIV 的 CVD 危险因素应作为 CVD 预防的重中之重,进行定期筛查和早期管理。